Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • Subscribe
  • My alerts
  • Log in
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
EditorialEditorial

Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors

Xiaodong Zhang, Chunyu Hou and Guang Yang
Cancer Biology & Medicine February 2022, 19 (2) 133-135; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0533
Xiaodong Zhang
1Department of Gastrointestinal Cancer Biology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaodong Zhang
  • For correspondence: [email protected]
Chunyu Hou
1Department of Gastrointestinal Cancer Biology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guang Yang
1Department of Gastrointestinal Cancer Biology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

Histone acetyltransferase 1 serves as a succinyl transferase in tumors

Protein post-translational modification (PTM) as an important research field has attracted increasing attention. Recently, our group has reported that histone acetyltransferase 1 (HAT1) succinylated histones and non-histones and promoted tumorigenesis1. HAT1 plays a role in different biological processes, including cell cycle progression, glucose metabolism, histone production, and DNA damage repair2. We found that HAT1 succinylated histone H3 on K122. For a non-histone, HAT1 catalyzed the succinylation of phosphoglycerate mutase 1 (PGAM1) on K99 to increase its enzyme activity, promoting glycolysis in cancer cells. Functionally, HAT1-mediated succinylation contributed to tumorigenesis. Our finding provided new insight into the mechanism of how a histone acetyltransferase HAT1 modulated succinylation during cancer development.

Highlighted multi-modifications mediated by a single enzyme

PTMs, which are alterations in the amino acid sequence of a protein after its synthesis, increase the functional diversity of the proteome by the covalent addition of functional groups or proteins, proteolytic cleavage of regulatory subunits, and degradation of entire proteins, which may be involved in the modification of amino acid side chains, terminal amino acids, or carboxyl groups by means of covalent or enzymatic modifications following protein biosynthesis3. Generally, these modifications influence the structure, stability, activity, cellular localization, and substrate specificities of proteins. In this study, we highlighted the significance of PTMs in tumors.

PTMs confer complexity to the proteome by adding diverse functions using a limiting the number of genes3. PTMs participate in the regulation of gene expression, modifying protein functions, and modulating interactions of proteins with DNA, cofactors, lipids, and other proteins, involving protein phosphorylation, protein methylation, and protein acetylation. Phosphorylation is an important PTM for modulating protein functions. The transfer of phosphate groups to the amino acid residues (serine, threonine, and tyrosine) of proteins catalyzed by protein kinases, and the binding of GTP under the action of signals, are common regulatory modes, which play important roles in the process of cell signal transduction4. Methylation is a covalent modification of arginine and lysine. Arginine can undergo monomethylation or dimethylation, while lysine can undergo monomethylation, dimethylation, or trimethylation5. Glycosylation is the process of attaching sugars to proteins or lipids under the control of enzymes, beginning in the endoplasmic reticulum and ending in the Golgi apparatus. Glycosyltransferases transfer sugars to proteins, forming glycosidic bonds with amino acid residues on proteins6. Sumoylation is analogous to ubiquitinylation in terms of the reaction scheme and enzyme classes. Sumoylation results in the addition of SUMOs (small ubiquitin-like modifiers), affecting the structure and subcellular localizations of proteins7. Hydroxylation attaches a hydroxylgroup (-OH) to a side chain of a protein, and is the most common reaction type in phase I metabolism. It usually produces a chemically stable and more polar hydroxylated metabolite than a drug8. Lysine succinylation (Ksuc or Ksucc) is a newly identified histone PTM that changes the chemical environment of histones and is similar to other acylation modifications. Lysine succinylation appears to accumulate at transcriptional start sites and to correlate with gene expression. Importantly, lysine succinylation plays an important role in cancers. In gastric cancer, overexpression of a succinylation-mimic mutant of lactate dehydrogenase A promotes cell proliferation, invasion, and migration9.

With the in-depth study of PTMs, it has been reported that an enzyme has a variety of modification functions, such as P300 as a transcriptional co-activator modulating the gene transcription through acylation of histones4,10. P300 is able to catalyze multiple types of lysine PTMs, such as acetylation, crotonylation, and lysine 2-hydroxyisobutyrylation11. HAT1 also has multiple functions, involving acetyltransferase, isobutyryltransferase, and succinylation activities on both histones and/or non-histones2,12–14. Nucleosomes are comprised of a core histone coatomer (2 copies each of histones H2A, H2B, H3, and H4), enclosed by ~147 bases of DNA. Whereas histone protein isoforms exist for H2A, H2B, and H3 (e.g., macro-H2A and cenH3), there are no histone H4 protein isoforms in animals2, indicating that H4 is a core subunit of all nucleosomes and may therefore represent a key focal point for regulation. For example, newly synthesized histone H4 is di-acetylated on lysines 5 and 12 by the cytosolic HAT115. For non-histones, HAT1 moderates the NF-κB response by regulating the transcription factor, PLZF12. Considering that HAT1 is an enzyme with multi-modification abilities, we predict that other enzymes may also involve multi-modifications in tumors. Based on its multiple regulatory functions, HAT1 may therefore serve as a precise therapeutic target in tumors.

Perspectives

Reprograming of protein PTMs

In recent years, with extensive studies of protein PTMs, the following research topics have arisen. Importantly, reprogramming of PTMs is observed in tumors. Accordingly, there is increased interest in the reprogramming of protein PTMs in tumors. What happens in tumors during reprogramming of PTMs? How do multi-modification enzymes function in tumors? What are the structural characteristics of enzymes with multiple catalytic activities? What are the relationships among these different catalytic functions? Does the function of catalytic pockets depend on its substrates? How do the various modification functions of enzymes play a coordinating role in tumors? To answer these questions, increasing studies should provide new insights into the mechanism by which the reprogramming of PTMs functions in tumors.

Enzymes with multi-modifications are ideal drug targets

PTMs are involved in many precise regulation mechanisms, playing crucial roles in cellular physiological and pathological processes16. However, the significance of PTMs in the development of cancer is poorly understood. Enzyme-mediated multi-modifications have a global influence in cancer progression. Notably, the multi-modifications mediated by enzymes in tumors, such as the P300 and HAT1 enzymes, should be extensively studied in the future. Furthermore, the network of multi-modifications mediated by one enzyme needs to be demonstrated in detail. The results may show that enzymes with multiple regulatory functions can serve as ideal drug targets in the treatment of tumors.

Conflict of interest statement

No potential conflicts of interest are disclosed.

  • Received September 28, 2021.
  • Accepted October 8, 2021.
  • Copyright: © 2022, Cancer Biology & Medicine
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    1. Yang G,
    2. Yuan Y,
    3. Yuan H,
    4. Wang J,
    5. Yun H,
    6. Geng Y, et al.
    Histone acetyltransferase 1 is a succinyltransferase for histones and non-histones and promotes tumorigenesis. EMBO Rep. 2021; 22: e50967.
  2. 2.↵
    1. Gruber JJ,
    2. Geller B,
    3. Lipchik AM,
    4. Chen J,
    5. Salahudeen AA,
    6. Ram AN, et al.
    HAT1 coordinates histone production and acetylation via H4 promoter binding. Mol Cell. 2019; 75: 711–24.
    OpenUrl
  3. 3.↵
    1. Wright P,
    2. Dyson H.
    Intrinsically disordered proteins in cellular signalling and regulation. Nat Rev Mol Cell Biol. 2015; 16: 18–29.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Pasek M.
    Thermodynamics of prebiotic phosphorylation. Chem Rev. 2020; 120: 4690–706.
    OpenUrl
  5. 5.↵
    1. Jambhekar A,
    2. Dhall A,
    3. Shi Y.
    Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019; 20: 625–41.
    OpenUrlCrossRef
  6. 6.↵
    1. Oliveira-Ferrer L,
    2. Legler K,
    3. Milde-Langosch K.
    Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017; 44: 141–52.
    OpenUrlCrossRef
  7. 7.↵
    1. Lemos M,
    2. Devi L.
    Post-translational modifications of opioid receptors. Trends Neurosci. 2020; 43: 417–32.
    OpenUrl
  8. 8.↵
    1. Gligorovski S,
    2. Strekowski R,
    3. Barbati S,
    4. Vione D.
    Environmental implications of hydroxyl radicals ((•)OH). Chem Rev. 2015; 115: 13051–92.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Li X,
    2. Zhang C,
    3. Zhao T,
    4. Su Z,
    5. Li M,
    6. Hu J, et al.
    Lysine-222 succinylation reduces lysosomal degradation of lactate dehydrogenase a and is increased in gastric cancer. J Exp Clin Cancer Res. 2020; 39: 172–88.
    OpenUrl
  10. 10.↵
    1. Dancy B,
    2. Cole P.
    Protein lysine acetylation by p300/CBP. Chem Rev. 2015; 115: 2419–52.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Huang H,
    2. Tang S,
    3. Ji M,
    4. Tang Z,
    5. Shimada M,
    6. Liu X, et al.
    p300-Mediated lysine 2-hydroxyisobutyrylation regulates glycolysis. Mol Cell. 2018; 70: 663–78.
    OpenUrlCrossRef
  12. 12.↵
    1. Sadler AJ,
    2. Suliman BA,
    3. Yu L,
    4. Yuan X,
    5. Wang D,
    6. Irving AT, et al.
    The acetyltransferase HAT1 moderates the NF-κB response by regulating the transcription factor PLZF. Nat Commun. 2015; 6: 6795–806.
    OpenUrlCrossRef
  13. 13.
    1. Agudelo P,
    2. Nagarajan P,
    3. Parthun MR.
    Hat1-dependent lysine acetylation targets diverse cellular functions. J Proteome Res. 2020; 19: 1663–73.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Yang G,
    2. Feng J,
    3. Liu Y,
    4. Zhao M,
    5. Yuan Y,
    6. Yuan H, et al.
    HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome. Theranostics. 2019; 9: 7345–58.
    OpenUrl
  15. 15.↵
    1. Nagarajan P,
    2. Ge Z,
    3. Sirbu B,
    4. Doughty C,
    5. Agudelo P,
    6. Schlederer M, et al.
    Histone acetyl transferase 1 is essential for mammalian development, genome stability, and the processing of newly synthesized histones H3 and H4. PLoS Genet. 2013; 9: e1003518.
  16. 16.↵
    1. Walsh C,
    2. Garneau S,
    3. Gatto G.
    Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed. 2005; 44: 7342–72.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 19 (2)
Cancer Biology & Medicine
Vol. 19, Issue 2
1 Feb 2022
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors
Xiaodong Zhang, Chunyu Hou, Guang Yang
Cancer Biology & Medicine Feb 2022, 19 (2) 133-135; DOI: 10.20892/j.issn.2095-3941.2021.0533

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors
Xiaodong Zhang, Chunyu Hou, Guang Yang
Cancer Biology & Medicine Feb 2022, 19 (2) 133-135; DOI: 10.20892/j.issn.2095-3941.2021.0533
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Histone acetyltransferase 1 serves as a succinyl transferase in tumors
    • Highlighted multi-modifications mediated by a single enzyme
    • Perspectives
    • Conflict of interest statement
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
  • The emerging role of long noncoding RNA RMRP in cancer development and targeted therapy
Show more Editorial

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2022 Cancer Biology & Medicine

Powered by HighWire